VYNE declares special dividend tied to pending Yarrow Bioscience merger

VYNE Therapeutics Inc. announced on July 10, 2026 that its board approved a special cash dividend connected to the company's pending merger with Yarrow Bioscience, Inc., under a merger agreement originally dated December 17, 2025. VYNE expects the dividend to total roughly $16.5 million, or about $0.38 per share, and it will go to stockholders and warrant holders on record as of July 22, 2026.¹

The company said the estimated amount reflects a good faith calculation of how much VYNE's net cash, as defined under the merger agreement, will exceed zero before the deal closes.¹ That per-share figure relies on 42,989,506 shares of common stock and common stock equivalents that were outstanding as of July 9, 2026.¹ VYNE plans to send the full payment to its transfer agent on July 23, 2026, and the actual amount could end up higher or lower than estimated; the transfer agent is then expected to distribute funds to shareholders within a few days.¹

The dividend payment depends on the merger closing, which VYNE expects around July 24, 2026, assuming stockholders approve the deal and other conditions are met.¹ A special stockholder meeting to vote on the merger is scheduled for 10:00 a.m. Eastern time on July 16, 2026.¹

Yarrow is described as a clinical-stage biotech working on treatments for autoimmune thyroid conditions. Its lead candidate, YB-101, is an antibody targeting the thyroid stimulating hormone receptor that the company says could become the first of its kind, aimed at directly interrupting the disease process behind Graves' disease and thyroid eye disease.¹